TY - JOUR
T1 - MOG antibody disease
T2 - A review of MOG antibody seropositive neuromyelitis optica spectrum disorder
AU - Narayan, Ram
AU - Simpson, Alexandra
AU - Fritsche, Katelyn
AU - Salama, Sara
AU - Pardo, Santiago
AU - Mealy, Maureen
AU - Paul, Friedemann
AU - Levy, Michael
N1 - Funding Information:
This work was supported by a grant from the National Institute of Neurological Disease and Stroke , NS-078555 (ML) . The funding source played no role in the design of the manuscript, the content or style, or provide any input or revisions.
Publisher Copyright:
© 2018 Elsevier B.V.
PY - 2018/10
Y1 - 2018/10
N2 - MOG antibody disease is an autoimmune disease of the central nervous system associated with a serological antibody against MOG, myelin oligodendrocyte glycoprotein. MOG is a glycoprotein expressed on the outer membrane of myelin and solely found within the central nervous system, including in the brain, optic nerves and spinal cord. Clinically, the disease resembles neuromyelitis optica spectrum disorders in the predilection for relapses of optic neuritis and transverse myelitis. In addition, acute disseminated encephalomyelitis (ADEM) is a well-recognized phenotype of MOG antibody disease in children. In recent studies around the world where MOG testing is available, up to 42% of NMOSD patients who test seronegative for the AQP4 antibody test positive for MOG antibodies. MOG antibody disease has thus recently emerged as a distinct entity carved out of the patient population diagnosed with NMOSD. In this review, we examine the history of the MOG antibody and its relevance to demyelinating disease, as well as compare the clinical, radiographic and serological profiles of patients with MOG antibody with patients with AQP4 antibody.
AB - MOG antibody disease is an autoimmune disease of the central nervous system associated with a serological antibody against MOG, myelin oligodendrocyte glycoprotein. MOG is a glycoprotein expressed on the outer membrane of myelin and solely found within the central nervous system, including in the brain, optic nerves and spinal cord. Clinically, the disease resembles neuromyelitis optica spectrum disorders in the predilection for relapses of optic neuritis and transverse myelitis. In addition, acute disseminated encephalomyelitis (ADEM) is a well-recognized phenotype of MOG antibody disease in children. In recent studies around the world where MOG testing is available, up to 42% of NMOSD patients who test seronegative for the AQP4 antibody test positive for MOG antibodies. MOG antibody disease has thus recently emerged as a distinct entity carved out of the patient population diagnosed with NMOSD. In this review, we examine the history of the MOG antibody and its relevance to demyelinating disease, as well as compare the clinical, radiographic and serological profiles of patients with MOG antibody with patients with AQP4 antibody.
UR - http://www.scopus.com/inward/record.url?scp=85050213964&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050213964&partnerID=8YFLogxK
U2 - 10.1016/j.msard.2018.07.025
DO - 10.1016/j.msard.2018.07.025
M3 - Review article
C2 - 30048919
AN - SCOPUS:85050213964
SN - 2211-0348
VL - 25
SP - 66
EP - 72
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
ER -